slides · global inventory
List
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 110,471
Current window 92,341-92,370
Pages 3,683
Rows per page 30
Component
92,341-92,370 of 110,471
13
The slide highlights the progression of delivery technology enabled by the ENHANZE license.argenx SE | Investor Conference Presentation Deck | 27 slides · argenx
Conference presentation Investor relations Beat · Rising SuccessLoop · Why Now1 hit
17
The slide uses an infinity-loop style diagram to connect three key pillars of the drug's value proposition.argenx SE | Investor Conference Presentation Deck | 27 slides · argenx
Conference presentation Investor relations Beat · The BreakthroughLoop · Quick Win Big Bet1 hit
18
Kaplan-Meier survival curve showing probability of being retreated with IVIg.argenx SE | Investor Conference Presentation Deck | 27 slides · argenx
Conference presentation Investor relations Beat · The BreakthroughLoop · Quick Win Big Bet1 hit
23
The diagram is a variation of a flywheel or infinity loop representing the integration of clinical development and disease insight.argenx SE | Investor Conference Presentation Deck | 27 slides · argenx
Conference presentation Investor relations Beat · Ultimate Achievement1 hit
26
argenx SE | Investor Conference Presentation Deck | 27 slidesargenx SE | Investor Conference Presentation Deck | 27 slides · argenx
Conference presentation Investor relations Beat · Ultimate Achievement1 hit
09
Includes specific drug names and market projections for 2028.AstraZeneca | Investor Conference Presentation Deck | 26 slides · AstraZeneca
Conference presentation Investor relations Beat · Rising SuccessLoop · Logic Chain1 hit
11
The slide uses a three-column layout to categorize business units and their respective growth drivers.AstraZeneca | Investor Conference Presentation Deck | 26 slides · AstraZeneca
Conference presentation Investor relations Beat · Rising Success1 hit
12
NME stands for New Molecular Entity. FDC stands for Fixed-Dose Combination.AstraZeneca | Investor Conference Presentation Deck | 26 slides · AstraZeneca
Conference presentation Investor relations Beat · Rising Success1 hit
13
Includes clinical development pipeline visualization and market growth projections.AstraZeneca | Investor Conference Presentation Deck | 26 slides · AstraZeneca
Conference presentation Investor relations Beat · Rising Success1 hit
14
Includes a table comparing hospitalization rates for RSV, hMPV, and Influenza across age groups.AstraZeneca | Investor Conference Presentation Deck | 26 slides · AstraZeneca
Conference presentation Investor relations Beat · Rising Success1 hit
16
The slide uses a waterfall-style growth diagram for Ultomiris and a combination of bar charts and bulleted metrics for HPP assets.AstraZeneca | Investor Conference Presentation Deck | 26 slides · AstraZeneca
Conference presentation Investor relations Beat · The BreakthroughLoop · Cost Of Inaction1 hit
20
Includes specific targets for 2025, 2026, and 2030.AstraZeneca | Investor Conference Presentation Deck | 26 slides · AstraZeneca
Conference presentation Investor relations Beat · Ultimate Achievement1 hit
21
The slide uses a four-column layout to highlight key strategic pillars.AstraZeneca | Investor Conference Presentation Deck | 26 slides · AstraZeneca
Conference presentation Investor relations Beat · Ultimate Achievement1 hit
03
Slide 03 of the deck.ATAI | Investor Presentation Deck | 34 slides · atai Life Sciences
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
07
Includes two line charts showing PK and PD profiles across different dosage levels.ATAI | Investor Presentation Deck | 34 slides · atai Life Sciences
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
12
The slide cites a third-party study (Palhano-Fontes et al.) as proxy evidence for DMT efficacy.ATAI | Investor Presentation Deck | 34 slides · atai Life Sciences
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
13
The slide uses a process flow diagram to show the progression of the trial parts.ATAI | Investor Presentation Deck | 34 slides · atai Life Sciences
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
15
The slide uses a line chart to show the change in MADRS scores over 12 weeks for three different dosages.ATAI | Investor Presentation Deck | 34 slides · atai Life Sciences
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
18
The chart illustrates the pharmacokinetic advantage of IV delivery over oral administration.ATAI | Investor Presentation Deck | 34 slides · atai Life Sciences
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
21
Includes a map of the world as a visual anchor for global disease burden.ATAI | Investor Presentation Deck | 34 slides · atai Life Sciences
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
22
The slide uses a line chart to show longitudinal changes in HCQ-29 subscales across three time points (Pre-dose, Discharge, 1 Month).ATAI | Investor Presentation Deck | 34 slides · atai Life Sciences
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
23
The slide outlines a clinical trial cohort structure and key safety/efficacy outcomes.ATAI | Investor Presentation Deck | 34 slides · atai Life Sciences
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
27
The slide demonstrates an inverted U-shaped dose response curve.ATAI | Investor Presentation Deck | 34 slides · atai Life Sciences
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
28
The slide uses a grouped bar chart to visualize T-scores across three cognitive tests (HVLT, Symbol Coding, Category Fluency) for four dosage cohorts.ATAI | Investor Presentation Deck | 34 slides · atai Life Sciences
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
29
The slide uses a standard clinical trial flow diagram showing randomization into three arms (40mg, 20mg, placebo) over a 6-week period.ATAI | Investor Presentation Deck | 34 slides · atai Life Sciences
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
32
Slide 32 of the deck.ATAI | Investor Presentation Deck | 34 slides · atai Life Sciences
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
05
BenevolentAI | Investor Conference Presentation Deck | 22 slidesBenevolentAI | Investor Conference Presentation Deck | 22 slides · BenevolentAI
Conference presentation Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
10
The slide uses a hub-and-spoke diagram to link the company to five specific capital allocation projects.BenevolentAI | Investor Conference Presentation Deck | 22 slides · BenevolentAI
Conference presentation Investor relations 1 hit
11
The slide uses a timeline-like structure to list six distinct value propositions.BenevolentAI | Investor Conference Presentation Deck | 22 slides · BenevolentAI
Conference presentation Investor relations 1 hit
12
Neon-style typography on a dark blue background.BenevolentAI | Investor Conference Presentation Deck | 22 slides · BenevolentAI
Conference presentation Investor relations 1 hit